SCK CEN And Quirem Medical Start Producing Ho-166 Microspheres At BR2 Reactor

SCK CEN and Quirem Medical announce the first production of holmium-166 microspheres for patient use at the BR2 reactor in Mol, Belgium.

A first clinical QuiremSpheres^® patient procedure took place with radioactive holmium-166 microspheres, an innovative product for treating liver cancer patients.

QuiremSpheres is the only commercially available product of its type that contains holmium-166 microspheres – essentially small spherical particles with diameters in the micrometer range.

Unlike the widely adopted yttrium-90 microspheres, holmium-166 microspheres can be visualized in low concentrations by means of Single Photon Emission Computed Tomography (SPECT) and Magnetic Resonance Imaging (MRI).

The procedure allows clinicians to assess the distribution of microspheres in the liver, enabling accurate evaluation of treatment directly after treatment.

Read the Quirem Press Release.